Skip to main content
NOXOPHARM LIMITED logo

NOXOPHARM LIMITED - Investor Relations & Filings

Listed IPO Jun 2016
Ticker · NOX ISIN · AU000000NOX9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 790 across all filing types
Latest filing 2025-12-11 Director's Dealing
Country AU Australia
Listing ASX NOX · 1 venue

About NOXOPHARM LIMITED

https://www.noxopharm.com

Noxopharm Limited is a clinical-stage drug development company focused on the discovery and development of novel treatments for cancer and inflammation. The company utilizes its proprietary drug discovery platforms, including Chroma and Sofra, to create a pipeline of therapeutic candidates. Its lead oncology asset, Veyonda, is designed to function as a radio-enhancer and chemo-sensitizer, aiming to improve the efficacy of existing cancer treatments. Additionally, the Sofra platform focuses on the development of synthetic oligonucleotides to modulate the immune system, specifically targeting toll-like receptors 7 and 8 to treat autoimmune and inflammatory diseases. Noxopharm also explores applications in mRNA vaccine technology through its SOF-VAC program, which aims to reduce the inflammatory side effects associated with mRNA-based therapeutics.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice - FB 2 pages 5.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director's Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including number of shares, options, and convertible notes acquired or disposed. The document is a formal notification of insider share transactions by a director, which aligns with the definition of Director's Dealing filings. The document length is 3912 characters, which is consistent with a detailed notice rather than a brief announcement. There is no indication that this is a financial report, management change, or other category. Therefore, the correct classification is Director's Dealing (DIRS).
2025-12-11 English
HERACLES clinical trial Update 5 3 pages 297.1KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing an update on the clinical trial progress of a drug candidate (SOF-SKN) by Noxopharm Limited. It provides details about the trial cohorts, safety assessments, and the drug's potential applications. There is no financial data, regulatory filing, or report attached or referenced. The content is an operational update related to clinical development rather than a financial or regulatory report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is also not a presentation, call transcript, or governance-related document. Given the nature of the content as a corporate announcement about clinical trial progress, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other specific categories.
2025-12-02 English
Noxopharm 2025 AGM Chair Address 3 pages 283.9KB
AGM Information Classification · 95% confidence The document is titled 'Noxopharm 2025 AGM Chair’s Address' and is clearly presented as the Chairman's speech at the 2025 Annual General Meeting. It contains a direct address to shareholders, discussing company progress, clinical trials, technology platforms, and shareholder appreciation. There are no detailed financial statements or comprehensive annual report content. The document length is 5628 characters, which is consistent with a speech or presentation rather than a full annual report. The content is typical of materials shared during an AGM meeting, specifically the Chairman's address. Therefore, the document fits the category of AGM Information (AGM-R).
2025-11-17 English
Noxopharm 2025 AGM Corporate Presentation 33 pages 4.2MB
AGM Information Classification · 95% confidence The document is titled 'Noxopharm 2025 AGM Corporate Presentation' and repeatedly references the AGM (Annual General Meeting) in the text and headings. It contains detailed presentation slides about the company's clinical trials, technology platforms, market opportunities, and financial summary, which are typical contents of an investor or corporate presentation given at an AGM. There is no indication that this is a full annual report, earnings release, or regulatory filing. The document is a presentation specifically prepared for the AGM event, not a report or announcement of voting results. Therefore, the most appropriate classification is AGM Information (AGM-R). The document length (15,000 characters) and detailed content support this classification with high confidence.
2025-11-17 English
Results of Meeting 3 pages 288.8KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Results of Annual General Meeting' and provides detailed voting outcomes for resolutions passed at the AGM held on 18 November 2025. It references compliance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act, which relate to disclosure of voting results. The content includes proxy vote counts and poll results for multiple resolutions, including adoption of the remuneration report and director re-election. There is no financial data or management discussion, only the official announcement of voting results. The document length is 6865 characters, which is consistent with a detailed voting results announcement rather than a full AGM presentation or annual report. Therefore, this document fits the category of 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2025-11-17 English
First dose in HERACLES clinical trial Part Two 3 pages 302.0KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the commencement of dosing in a clinical trial (HERACLES Part Two) for a drug candidate SOF-SKN by Noxopharm Limited. It discusses the trial design, goals, and market potential but contains no financial data, regulatory filings, or detailed financial reports. It is not an earnings release, annual report, or any financial report. It is also not a regulatory filing or certification. The document is an update on clinical trial progress and company development, typical of a general regulatory announcement or corporate update. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2025-11-16 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.